Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AGEN | Common Stock | Options Exercise | $400K | +119K | +16.24% | $3.36 | 853K | Sep 13, 2021 | Direct | F1 |
transaction | AGEN | Common Stock | Sale | -$534K | -82.1K | -9.63% | $6.50 | 771K | Sep 13, 2021 | Direct | F4 |
holding | AGEN | Common Stock | 126K | Sep 13, 2021 | See Footnote | F2 | |||||
holding | AGEN | Common Stock | 579K | Sep 13, 2021 | See Footnote | F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AGEN | Stock Option, right to buy | Options Exercise | $0 | -119K | -100% | $0.00* | 0 | Sep 13, 2021 | Common Stock | 119K | $3.36 | Direct |
Id | Content |
---|---|
F1 | The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021. |
F2 | Shares are held in Dr. Armen's IRA accounts. |
F3 | Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 479,000 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein. |
F4 | Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.55. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |